Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT05425576
Title OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Oncotelic Inc.
Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.